

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability under the Companies Ordinance)

(Stock Code: 00656)

ANNOUNCEMENT PRINCIPAL FINANCIAL DATA AND INDICATORS OF FOSUN PHARMA FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2012

On 30 October 2012, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("**Fosun Pharma**"), a subsidiary of Fosun International Limited (the "**Company**") with its A shares listed and traded on the Shanghai Stock Exchange (Stock Code: 600196) and its H shares listed and traded on The Stock Exchange of Hong Kong Limited (Stock Code: 02196), issued an announcement in relation to the extract of the 2012 third quarter report (the "**Announcement**").

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal financial data and indicators of Fosun Pharma for the nine months ended 30 September 2012 as set out in the Announcement:

Principal Financial Data and Indicators of Fosun Pharma

Currency: RMB

	As at the end of this reporting period	As at the end of last year	Increase/decrease as at the end of this reporting period as compared with the end of last year (%)
Total assets (yuan)	22,404,889,659.15	22,290,818,173.51	0.51
Owners' equity (or shareholders' equity) (yuan)	10,203,924,131.22	9,771,863,023.84	4.42
Equity per share attributable to shareholders of the listed company (yuan/share)	5.36	5.13	4.42

	From the beginning of 2012 up to the end of this reporting period (January - September)		Increase/decrease as compared with the same period last year (%)
Net cash flow from operating activities (yuan)	415,490,491.69		619.62
Net cash flow per share from operating activities (yuan/share)	0.22		619.62
	Reporting period (July - September)	From the beginning of 2012 up to the end of this reporting period (January - September)	Increase/decrease of this reporting period as compared with the same period last year (%)
Net profit attributable to shareholders of the listed company (yuan)	391,456,294.41	1,093,223,251.90	94.90
Basic earnings per share (yuan/share)	0.21	0.57	94.90
Basic earnings per share net of non-recurring gain or loss (yuan/share)	0.12	0.33	44.76
Diluted earnings per share (yuan/share)	0.21	0.57	94.90
Weighted average return on equity (%)	3.85	10.93	Increased by 1.76 percentage points
Weighted average return on equity net of non-recurring gain or loss (%)	2.32	6.38	Increased by 0.62 percentage point

Items and amounts of non-recurring gain or loss:

Unit: Yuan Currency: RMB

Items	Amount incurred from the beginning of 2012 up to the end of this reporting period (January - September)	Explanation
Gains or losses from disposal of non-current assets	237,445,385.48	Mainly due to gains arising from disposal of long-term equity investments during the reporting period
Government grants (except for continuous government grants which are closely related to the normal operating business of the company and granted according to certain standardised amounts or quotas subject to national policy provision) included in gains or losses for the current period	22,467,563.02	
Gains or losses from changes in fair values of trading financial assets and trading financial liabilities held by the company, and investment gains from disposal of trading financial assets and trading financial liabilities and available-for-sale financial assets, other than effective hedging activities associated with normal business operations of the company	422,032,649.58	Mainly due to gains arising from disposal of available-for-sale financial assets during the reporting period

Other non-operating income and expenses apart from the foregoing	2,353,545.77	
Effect of income tax	-171,610,351.86	
Effect of minority equity (after tax)	-56,885,721.07	
Total	455,803,070.92	

Note: The full text of the 2012 third quarter report of Fosun Pharma and the Announcement will be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>).

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

Shanghai, the PRC, 30 October 2012

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Andrew Y. Yan, Mr. Zhang Huaqiao and Mr. David T. Zhang.